KB Medical raised CHF 2.5MM (~US $2.51MM) in a Series B Financing. Funds will support FDA approval and upgrade validations for the AQrate™ Robotic Assistance System V 1.2 for spinal surgery.
The company’s first product has completed clinical trials in spinal fusion on 24 patients and received CE Mark approval in 2Q16. Restricted launch will begin in 2017.
Additional functionality to be added to AQrate includes proprietary anti-skiving technology.
Sources: KB Medical SA; ORTHOWORLD Inc.
KB Medical raised CHF 2.5MM (~US $2.51MM) in a Series B Financing. Funds will support FDA approval and upgrade validations for the AQrate™ Robotic Assistance System V 1.2 for spinal surgery.
The company's first product has completed clinical trials in...
KB Medical raised CHF 2.5MM (~US $2.51MM) in a Series B Financing. Funds will support FDA approval and upgrade validations for the AQrate™ Robotic Assistance System V 1.2 for spinal surgery.
The company’s first product has completed clinical trials in spinal fusion on 24 patients and received CE Mark approval in 2Q16. Restricted launch will begin in 2017.
Additional functionality to be added to AQrate includes proprietary anti-skiving technology.
Sources: KB Medical SA; ORTHOWORLD Inc.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
